RE/MAX Holdings supplemented its joint proxy/prospectus to disclose the expected Real REMAX Group board composition, updated J.P. Morgan valuation analyses and additional litigation-related disclosures.

Key Highlights:

  • Announces Real REMAX Group board slate of 11 directors (including Chair Tamir Poleg) and one Director Emeritus; committee assignments disclosed.
  • Audit, Compensation and Nominating/Gov't committees and members named; Larry Klane to chair Audit Committee (audit expert).
  • J.P. Morgan updated valuation metrics: FV/2026E EBITDA multiples and DCF ranges imply REMAX $10.50–$14.00/share and Real $2.50–$3.00/share.
  • Supplement notes two stockholder demand letters and two NY lawsuits challenging disclosures; parties voluntarily added supplemental disclosures while denying wrongdoing.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.